Literature DB >> 9222342

HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings.

M Nakagawa1, S Izumo, S Ijichi, H Kubota, K Arimura, M Kawabata, M Osame.   

Abstract

We studied the clinical features and laboratory findings in 213 patients with HTLV-I-associated myelopathy/tropical spastic paraparesis as diagnosed in Kagoshima University Hospital. Some aspects of clinical features in HTLV-I-associated myelopathy/tropical spastic paraparesis were characterized by mode of HTLV-I transmission and age of onset. The patients with onset after 15 years old and no history of blood transfusion before the onset of the disease (151 patients, group I) showed a shorter interval between the time of disease onset and that of inability to walk. The patients with onset before 15 years old and without history of blood transfusion (21 patients, group II) had short stature and slow progression of the disease. The interval time and the progression of the disease in patients with history of blood transfusion before onset of disease (41 patients, group III) were in between those of the above two groups. Patients whose ages of onset were older than 61 years old showed a faster progression than those with younger onset regardless of the mode of HTLV-I transmission. HTLV-I-associated myelopathy/tropical spastic paraparesis patients often also showed other organ disorders such as leukoencephalopathy (69%), abnormal findings on chest X-ray (50%), Sjögren syndrome (25%) and arthropathy (17%). The patients with low anti-HTLV-I antibody titers in the cerebrospinal fluid (2X-8X by PA method) had an older age of onset on average, milder clinical symptoms and lesser increase of neopterin in the cerebrospinal fluid than those in the high titer subgroup whose titers were higher than 1024X in cerebrospinal fluid regardless of the mode of HTLV-I transmission. We speculate that the clinical course of HTLV-I-associated myelopathy/tropical spastic paraparesis mainly shows a slow progression which consists of an initial progressive phase (probably an inflammatory phase) and a latter chronic phase, although some patients showed acute/subacute onset and rapid progression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9222342     DOI: 10.3109/13550289509111010

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  72 in total

1.  HTLV-I-associated myelopathy: acute progression and atypical MR findings.

Authors:  M Shakudo; Y Inoue; T Tsutada
Journal:  AJNR Am J Neuroradiol       Date:  1999-09       Impact factor: 3.825

2.  HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years.

Authors:  T Matsuzaki; M Nakagawa; M Nagai; K Usuku; I Higuchi; K Arimura; H Kubota; S Izumo; S Akiba; M Osame
Journal:  J Neurovirol       Date:  2001-06       Impact factor: 2.643

Review 3.  HTLV-1 infections.

Authors:  C R Bangham
Journal:  J Clin Pathol       Date:  2000-08       Impact factor: 3.411

4.  Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting.

Authors:  David Yurick; Georges Khoury; Bridie Clemens; Liyen Loh; Hai Pham; Katherine Kedzierska; Lloyd Einsiedel; Damian Purcell
Journal:  J Clin Microbiol       Date:  2019-01-30       Impact factor: 5.948

5.  Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  M Makino; M Azuma; S I Wakamatsu; Y Suruga; S Izumo; M M Yokoyama; M Baba
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

6.  A tax on luxury: HTLV-I infection of CD4+CD25+ Tregs.

Authors:  Robert S Fujinami
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

7.  Genetic variability in the extracellular matrix protein as a determinant of risk for developing HTLV-I-associated neurological disease.

Authors:  Yasuyuki Nobuhara; Koichiro Usuku; Mineki Saito; Shuji Izumo; Kimiyoshi Arimura; Charles R M Bangham; Mitsuhiro Osame
Journal:  Immunogenetics       Date:  2006-01-10       Impact factor: 2.846

Review 8.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

9.  Subacute progression of human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  Marco A Lima; Ramza C Harab; Doris Schor; Maria J Andrada-Serpa; Abelardo Q C Araújo
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

10.  Genes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.

Authors:  Mariana Tomazini Pinto; Tathiane Maistro Malta; Evandra Strazza Rodrigues; Daniel Guariz Pinheiro; Rodrigo Alexandre Panepucci; Kelen Cristina Ribeiro Malmegrim de Farias; Alessandra De Paula Sousa; Osvaldo Massaiti Takayanagui; Yuetsu Tanaka; Dimas Tadeu Covas; Simone Kashima
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-16       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.